Mucin 16 and kallikrein 13 as potential prognostic factors in colon cancer: Results of an oncological 92-multiplex immunoassay
Colon cancer represents one of the most common cancers in the world. Despite improved treatment, mortality remains high. In order to improve the assessment of prognosis for colon cancer patients, identifying new prognostic markers remains necessary. We analyzed preoperative serum samples from 148 co...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-07-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428319860728 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849416854167093248 |
|---|---|
| author | Kajsa Björkman Harri Mustonen Tuomas Kaprio Caj Haglund Camilla Böckelman |
| author_facet | Kajsa Björkman Harri Mustonen Tuomas Kaprio Caj Haglund Camilla Böckelman |
| author_sort | Kajsa Björkman |
| collection | DOAJ |
| description | Colon cancer represents one of the most common cancers in the world. Despite improved treatment, mortality remains high. In order to improve the assessment of prognosis for colon cancer patients, identifying new prognostic markers remains necessary. We analyzed preoperative serum samples from 148 colon cancer patients surgically treated at Helsinki University Hospital from 1998 through 2002 using a multiplex proximity extension assay (Oncology II panel, Olink Bioscience, Uppsala, Sweden), a panel constituting 92 immunological and oncological markers. We performed univariate and multivariate analyses on these patients and calculated the disease-specific survival among patients using the log-rank test for Kaplan–Meier estimates. In the univariate survival analysis of 92 biomarkers, 26 resulted in p < 0.1. Among these, eight biomarkers emerged as statistically significant (p < 0.05). Patients with low levels of kallikrein 13 had a poor prognosis. Moreover, patients with high levels of amphiregulin, carcinoembryonic antigen-related adhesion molecule 5, interleukin 6, mucin 16, syndecan 1, transforming growth factor alpha, and vimentin also had a poor prognosis. In the multivariate analysis, kallikrein 13 and mucin 16 emerged as independent prognostic markers. The role of kallikrein 13, a member of the serine protease kallikrein biomarker family, in tumorigenesis remains unclear. Mucin 16 is also known as carbohydrate antigen 125, a well-known ovarian cancer biomarker. Patients with low levels of kallikrein 13 (hazard ratio: 0.36; 95% confidence interval: 0.14–0.92; p = 0.033) and high levels of mucin 16 (hazard ratio: 3.15; 95% confidence interval: 1.68–5.93; p < 0.005) had a poor prognosis. Mucin 16 and kallikrein 13 represent independent prognostic markers for colon cancer. Furthermore, the clinical utility of mucin 16 and kallikrein 13 serum tests warrants additional investigation. |
| format | Article |
| id | doaj-art-49396f879c9d4e859e9ff94038f00f79 |
| institution | Kabale University |
| issn | 1423-0380 |
| language | English |
| publishDate | 2019-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Tumor Biology |
| spelling | doaj-art-49396f879c9d4e859e9ff94038f00f792025-08-20T03:33:02ZengSAGE PublishingTumor Biology1423-03802019-07-014110.1177/1010428319860728Mucin 16 and kallikrein 13 as potential prognostic factors in colon cancer: Results of an oncological 92-multiplex immunoassayKajsa Björkman0Harri Mustonen1Tuomas Kaprio2Caj Haglund3Camilla Böckelman4Meilahti Hospital, Helsinki, FinlandResearch Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, FinlandResearch Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, FinlandHelsinki University Hospital, Helsinki, FinlandHelsinki University Hospital, Helsinki, FinlandColon cancer represents one of the most common cancers in the world. Despite improved treatment, mortality remains high. In order to improve the assessment of prognosis for colon cancer patients, identifying new prognostic markers remains necessary. We analyzed preoperative serum samples from 148 colon cancer patients surgically treated at Helsinki University Hospital from 1998 through 2002 using a multiplex proximity extension assay (Oncology II panel, Olink Bioscience, Uppsala, Sweden), a panel constituting 92 immunological and oncological markers. We performed univariate and multivariate analyses on these patients and calculated the disease-specific survival among patients using the log-rank test for Kaplan–Meier estimates. In the univariate survival analysis of 92 biomarkers, 26 resulted in p < 0.1. Among these, eight biomarkers emerged as statistically significant (p < 0.05). Patients with low levels of kallikrein 13 had a poor prognosis. Moreover, patients with high levels of amphiregulin, carcinoembryonic antigen-related adhesion molecule 5, interleukin 6, mucin 16, syndecan 1, transforming growth factor alpha, and vimentin also had a poor prognosis. In the multivariate analysis, kallikrein 13 and mucin 16 emerged as independent prognostic markers. The role of kallikrein 13, a member of the serine protease kallikrein biomarker family, in tumorigenesis remains unclear. Mucin 16 is also known as carbohydrate antigen 125, a well-known ovarian cancer biomarker. Patients with low levels of kallikrein 13 (hazard ratio: 0.36; 95% confidence interval: 0.14–0.92; p = 0.033) and high levels of mucin 16 (hazard ratio: 3.15; 95% confidence interval: 1.68–5.93; p < 0.005) had a poor prognosis. Mucin 16 and kallikrein 13 represent independent prognostic markers for colon cancer. Furthermore, the clinical utility of mucin 16 and kallikrein 13 serum tests warrants additional investigation.https://doi.org/10.1177/1010428319860728 |
| spellingShingle | Kajsa Björkman Harri Mustonen Tuomas Kaprio Caj Haglund Camilla Böckelman Mucin 16 and kallikrein 13 as potential prognostic factors in colon cancer: Results of an oncological 92-multiplex immunoassay Tumor Biology |
| title | Mucin 16 and kallikrein 13 as potential prognostic factors in colon cancer: Results of an oncological 92-multiplex immunoassay |
| title_full | Mucin 16 and kallikrein 13 as potential prognostic factors in colon cancer: Results of an oncological 92-multiplex immunoassay |
| title_fullStr | Mucin 16 and kallikrein 13 as potential prognostic factors in colon cancer: Results of an oncological 92-multiplex immunoassay |
| title_full_unstemmed | Mucin 16 and kallikrein 13 as potential prognostic factors in colon cancer: Results of an oncological 92-multiplex immunoassay |
| title_short | Mucin 16 and kallikrein 13 as potential prognostic factors in colon cancer: Results of an oncological 92-multiplex immunoassay |
| title_sort | mucin 16 and kallikrein 13 as potential prognostic factors in colon cancer results of an oncological 92 multiplex immunoassay |
| url | https://doi.org/10.1177/1010428319860728 |
| work_keys_str_mv | AT kajsabjorkman mucin16andkallikrein13aspotentialprognosticfactorsincoloncancerresultsofanoncological92multipleximmunoassay AT harrimustonen mucin16andkallikrein13aspotentialprognosticfactorsincoloncancerresultsofanoncological92multipleximmunoassay AT tuomaskaprio mucin16andkallikrein13aspotentialprognosticfactorsincoloncancerresultsofanoncological92multipleximmunoassay AT cajhaglund mucin16andkallikrein13aspotentialprognosticfactorsincoloncancerresultsofanoncological92multipleximmunoassay AT camillabockelman mucin16andkallikrein13aspotentialprognosticfactorsincoloncancerresultsofanoncological92multipleximmunoassay |